This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Soligenix Yönetim

Yönetim kriter kontrolleri 2/4

Soligenix CEO'su Christopher Schaber, Aug2006 tarihinde atandı, in görev süresi 16.75 yıldır. in toplam yıllık tazminatı $ 711.19K olup, şirket hissesi ve opsiyonları dahil olmak üzere 70.2% maaş ve 29.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.2% ine doğrudan sahiptir ve bu hisseler € 16.11K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.9 yıl ve 13.9 yıldır.

Anahtar bilgiler

Christopher Schaber

İcra Kurulu Başkanı

US$711.2k

Toplam tazminat

CEO maaş yüzdesi	70.23%
CEO görev süresi	16.8yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	8.9yrs
Yönetim Kurulu ortalama görev süresi	13.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Christopher Schaber'un ücretlendirmesi Soligenix'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$619k	US$453k	-US$9m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$674k	US$444k	-US$7m
Sep 30 2017	n/a	n/a	-US$5m
Jun 30 2017	n/a	n/a	-US$6m
Mar 31 2017	n/a	n/a	-US$4m
Dec 31 2016	US$598k	US$435k	-US$3m

Tazminat ve Piyasa: Christopher 'nin toplam tazminatı ($USD 711.19K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 415.71K ).

Tazminat ve Kazançlar: Christopher şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Christopher Schaber (56 yo)

16.8yrs

Görev süresi

US$711,186

Tazminat

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Schaber	Chairman of the Board of Directors	16.8yrs	US$711.19k	0.20% € 16.1k
Jonathan Guarino	Senior VP	3.7yrs	US$355.35k	0.025% € 2.0k
Oreola Donini	Senior VP & Chief Scientific Officer	8.4yrs	US$364.24k	0% € 0
Richard Straube	Senior VP & Chief Medical Officer	9.3yrs	US$242.33k	0.018% € 1.4k

8.9yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: DOA 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Schaber	Chairman of the Board of Directors	16.8yrs	US$711.19k	0.20% € 16.1k
Jerome Zeldis	Independent Director	11.9yrs	US$80.00k	0.052% € 4.1k
Gregory Lapointe	Independent Director	14.2yrs	US$87.50k	0.017% € 1.3k
Robert Rubin	Independent Director	13.6yrs	US$85.00k	0.010% € 785.2
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	Veri yok	Veri yok
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	Veri yok	Veri yok
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	Veri yok	Veri yok
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	Veri yok	Veri yok
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	Veri yok	Veri yok
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	Veri yok	Veri yok
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	Veri yok	Veri yok
Gary Wood	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	Veri yok	Veri yok

13.9yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DOA 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 13.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2023/05/09 22:37
Gün Sonu Hisse Fiyatı	2023/02/09 00:00
Kazançlar	2022/12/31
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Soligenix, Inc. 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
Andrew D'Silva	B. Riley Securities, Inc.
Keith Markey	Griffin Securities

This company listing is no longer active

Soligenix Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, Jun 20, 2025

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Recent updates

Soligenix Achieves Important Safety Milestone in Its Confirmatory Phase 3 Clinical Trial of Hybryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc. has completed a Follow-on Equity Offering in the amount of $7.500006 million.

Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $7.999998 million.

Soligenix, Inc. Announces Publication Recommending Long-Term High Temperature Stability of Protein Subunit Vaccines forbola and Related Viruses

Soligenix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for its Common Stock

Soligenix Inc. Announces Audio Press Release on Promising First-Line Therapy for Rare Skin Cancer

Soligenix, Inc. Completes its Phase 2a Proof of Concept Study Evaluating SGX945 (Dusquetide) in Treatment of Behcet's Disease and Achieves Study Objective of Demonstrating Biological Efficacy

Soligenix, Inc. Announces Synthetic Hypericin Successfully Manufactured At Sterling Pharma Solutions

Soligenix, Inc. Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte in Ongoing Clinical Trials

Soligenix, Inc., Annual General Meeting, Jun 20, 2025

Soligenix, Inc. Announces Interim Results from the Ongoing Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte

Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

CEO Tazminat Analizi

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları